Neos Therapeutics at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference (Replay)
12/14/17 at 3:00 p.m. ET
Corporate ProfileNeos Therapeutics develops, manufactures, and commercializes innovative extended-release (XR) products using our proprietary extended-release drug delivery and orally disintegrating tablet (ODT) technology platforms. We have two FDA approved products for the treatment of ADHD and both utilize our extended-release ODT technology. Our third branded ADHD product candidate is an extended-release oral suspension. Our growing ADHD Product Portfolio puts Neos in a unique position to meet the different needs of patients that struggle with ADHD.
- 11/28/17Neos Therapeutics to Participate in Two December Conferences
- 11/08/17Neos Therapeutics Reports Third Quarter 2017 Financial Results
- 11/07/17Neos Therapeutics to Present at the Stifel 2017 Healthcare Conference
- 11/02/17Neos Therapeutics to Host Third Quarter 2017 Financial Results Conference Call on November 8, 2017